Avidity Biosciences

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , Oct. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on October 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 421,600 shares of its common stock and 210,800 restricted stock units ("RSUs") to thirty-four (34) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The three-horse race to treat a devastating form of muscular dystrophy is now down to two. And Avidity Biosciences is feeling bullish.

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

The company's most promising pipeline program can continue unabated.

Why Avidity Biosciences Zoomed to a 12% Gain This Week

SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: Chardan 8th Annual Genetic Medicines Conference on October 1 at 7:30 a.m.

Avidity Biosciences to Participate in Upcoming Investor Conference

Goldman Sachs has initiated coverage on Avidity Biosciences Inc RNA based on multi-blockbuster, first-to-market commercial opportunities for its investigational candidates.

Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases

Corbus Pharmaceuticals Holdings

Viking Therapeutics

The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry.

3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024

Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity reported groundbreaking data in all three clinical programs addressing rare muscular dystrophies: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44) SAN DIEGO , Sept. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining with patient and advocacy communities to raise awareness during National Muscular Dystrophy Awareness Month, an annual observance that takes place every September to support families who are impacted by neuromuscular diseases.

Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month

SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: Wells Fargo 2024 Healthcare Conference on September 4 at 5:00 a.m. PT / 8:00 a.m.

Avidity Biosciences to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Life Science Cares San Diego (LSC), a nonprofit organization activating the financial and human capital of the life sciences industry and partnering with local nonprofits to disrupt the cycle of poverty and inequity throughout its communities, and Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced a $250,000 grant from Avidity to Life Science Care.

Life Science Cares San Diego Scales Partnership with Avidity Biosciences Through Life Science Shares Program

SAN DIEGO , Aug. 19, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 8,418,000 shares of its common stock, including 1,098,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $41.00 per share. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $345.1 million.

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

However, even with this massive appreciation, Wall Street analysts still see a solid upside in the stock. Based on recent analyst changes, the average price target is $62, implying an upside of 39%.

This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?

Avidity Biosciences, Inc. achieved positive results from phase 1/2 FORTITUDE study, using Del-brax for the treatment of patients with FSHD. Positive results achieved from phase 1/2 EXPLORE44 study, using Del-zota for the treatment of patients with DMD. The Phase 3 HARBOR study, using Del-desiran for the treatment of patients with myotonic dystrophy type 1, was initiated in June 2024.

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

SAN DIEGO , Aug. 14, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its upsized underwritten public offering of 7,320,000 shares of its common stock at a price to the public of $41.00 per share. All of the shares to be sold in the offering are to be sold by Avidity.

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock.

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.66 per share a year ago.

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates

Avidity reports positive del-zota (AOC 1044) data; demonstrated 25% increase in dystrophin production and reduction of creatine kinase levels to near normal in people living with DMD44 in Phase 1/2 EXPLORE44™ trial Initiated global Phase 3 HARBOR™ trial and began administration of del-desiran in people living with DM1; del-desiran received FDA Breakthrough Therapy designation Avidity plans to accelerate initiation of del-brax (AOC 1020) registrational cohorts after reporting unprecedented and consistent reductions in DUX4 regulated genes, trends of functional improvement and favorable safety and tolerability in people living with FSHD in Phase 1/2 FORTITUDE™ trial Announcement of our lead precision cardiology program target planned for Q4 2024 Cash on hand of approximately $1.3 billion SAN DIEGO , Aug. 9, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "The last few months have been incredible for Avidity, but more importantly, for people living with DM1, FSHD and DMD.

Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights

Avidity unveiled promising results for its DMD treatment on Friday and the top-notch biotech stock catapulted. RNA stock is highly rated.

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics

SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of John B. Moriarty, Jr., J.D.

Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer

Jumia

MicroStrategy Incorporated

With a bull market barely showing signs of slowing down, one of the best outperforming stocks this year is Super Micro Computer (NASDAQ: SMCI ). The premier provider of AI-optimized computers, servers, networks, storage solutions and data center workstations is up 176% year-to-date.

3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)

Longboard Pharmaceuticals

SoundHound AI Inc

Interest rate cuts may could provide a major catalyst for Russell 2000 listed stocks. These three Russell 2000 constituents warrant a serious look by growth investors right now.

3 Russell 2000 Growth Stocks That Could Be Worth the Risk

Contineum Therapeutics Inc

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an indepen.

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

FSHD Society to host Avidity webinar on positive initial data from the Phase 1/2 FORTITUDE™ trial for people living with FSHD today at 1:00 p.m. ET SAN DIEGO , June 20, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is partnering with the FSHD Society and joining the global community of patients, caregivers, and healthcare providers to raise awareness of facioscapulohumeral muscular dystrophy in support of World FSHD Day.

Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day

SAN DIEGO , June 17, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 12,132,500 shares of its common stock, including 1,582,500 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $38.00 per share. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $461.0 million.

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO , June 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 10,550,000 shares of its common stock at a price to the public of $38.00 per share. All of the shares to be sold in the offering are to be sold by Avidity.

Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.

News for Avidity Biosciences Stock (RNA)